oxidative damage found to be present in early Alzheimer's disease. This early mild cognitive impairment is the time for treatment to delay disease progression. As this study points out, most studies up to this point have been done on individuals with late Alzheimer's disease. This show that oxidative damage plays a prominent role in disease development. This study found oxidative damage through several markers: lipid peroxides,isoprostanes, 8-hydroxy-2-deoxyguanosine...
Astaxanthin at 20 mg found to reduce oxidized LDL and other oxidative stress biomarkers as assessed by Malondialdehydy, SOD, Isoprostane, and TAC. The dose was 20 mg for 12 weeks. This higher dose was associated with minimal side effects--red stools.